Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
https://doi.org/10.14341/DM7745
Abstract
Intensification of antihyperglycaemic treatment in patients with poorly controlled type 2 diabetes mellitus who were on insulin therapy remains a difficult issue. Results from clinical trials with the sodium-glucose linked transporter (SGLT-2) inhibitor dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus using insulin are summarised and discussed in the article.
About the Authors
Olga Yuryevna Sukhareva
Endocrinology Research Centre
Russian Federation
MD, PhD
Russian Federation
MD, PhD
Marina Vladimirovna Shestakova
Endocrinology Research Centre;
Sechenov First Moscow State Medical University
Russian Federation
MD, PhD, Professor
Russian Federation
MD, PhD, Professor
References
1. Nauck M. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014:1335. doi: 10.2147/dddt.s50773
2. Wilding JPH, Norwood P, T’Joen C, et al. A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care.2009;32(9):1656-1662. doi: 10.2337/dc09-0517
3. Wilding JPH. Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin. Ann Intern Med. 2012;156(6):405. doi: 10.7326/0003-4819-156-6-201203200-00003
4. Wilding JPH, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124-136. doi: 10.1111/dom.12187
5. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Ann Intern Med. 2013;159(4):262. doi: 10.7326/0003-4819-159-4-201308200-00007
6. AstraZeneca and Bristol-Myers Squibb. Dapagliflozin Summary of Product Characteristics (SmPC). 2013. Available from: http://www.forxiga.eu/Forxiga%20Summary%20of%20Product%20Characteristics_SmPC_.pdf
7. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine. 2013;11(1):43. doi: 10.1186/1741-7015-11-43
8. Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab.2015;17(6):581-590. doi: 10.1111/dom.12459
9. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. – 2015. – Т. 18. – №1S. – C. 1-112. [Dedov II, Shestakova MV, Aleksandrov AA, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (7th edition). Diabetes mellitus. 2018;18(1S):1-112. (In Russ)] doi: 10.14341/DM20151S
10. Ptaszynska A, Johnsson KM, Apanovitch AM, et al. Safety of dapagliflozin in Clinical Trials for T2DM. Diabetes. 2012;61:A258. [Abstract 1011-P].
Supplementary files
Review
For citations:
Sukhareva O.Yu., Shestakova M.V. Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin. Diabetes mellitus. 2016;19(1):72-79. (In Russ.) https://doi.org/10.14341/DM7745
Views:
11817
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
